X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (7) 7
index medicus (6) 6
hematopoietic stem (5) 5
humans (5) 5
aged (4) 4
chemotherapy (4) 4
colony-stimulating factor (4) 4
count recovery (4) 4
female (4) 4
hematopoietic stem cell mobilization - methods (4) 4
male (4) 4
multiple-myeloma (4) 4
outcome (4) 4
plerixafor (4) 4
analysis (3) 3
autologous transplantation (3) 3
cyclophosphamide (3) 3
immune recovery (3) 3
lymphoma, non-hodgkin - therapy (3) 3
middle aged (3) 3
multiple myeloma (3) 3
multiple myeloma - therapy (3) 3
oncology (3) 3
plus g-csf (3) 3
predicts superior survival (3) 3
adult (2) 2
antigens, cd34 - analysis (2) 2
b cells (2) 2
blood (2) 2
cd34 cells (2) 2
graft survival (2) 2
hematopoietic stem cell transplantation - methods (2) 2
hematopoietic stem cells - drug effects (2) 2
hematopoietic stem cells - metabolism (2) 2
heterocyclic compounds - administration & dosage (2) 2
lymphocyte count (2) 2
lymphoma (2) 2
lymphoma, non-hodgkin - mortality (2) 2
phase-ii (2) 2
plerixafor injection (2) 2
previously failing mobilization (2) 2
progression-free survival (2) 2
prospective studies (2) 2
stem cells (2) 2
stem-cell transplantation (2) 2
transplantation, autologous (2) 2
treatment outcome (2) 2
alc-15 (1) 1
anti-hiv agents - administration & dosage (1) 1
antigens, cd34 (1) 1
antigens, cd34 - drug effects (1) 1
apheresis (1) 1
auto-sct (1) 1
autograft lymphocyte (1) 1
autografts (1) 1
autografts - cytology (1) 1
autologous hematopoietic cell transplantation (1) 1
autologous stem cell transplantation (1) 1
bortezomib (1) 1
case-control studies (1) 1
cd34 antigen (1) 1
clinical trials, phase ii as topic (1) 1
clinical trials, phase iii as topic (1) 1
collection (1) 1
combined modality therapy (1) 1
cost-benefit analysis (1) 1
costs (1) 1
cryopreservation (1) 1
cyclophosphamide - pharmacology (1) 1
cyclophosphamide - therapeutic use (1) 1
cytometry (1) 1
dexamethasone (1) 1
dexamethasone combination (1) 1
diagnosed multiple-myeloma (1) 1
disease-free survival (1) 1
dosage and administration (1) 1
early lymphocyte recovery (1) 1
engraftment (1) 1
engraftment kinetics (1) 1
factor g-csf (1) 1
flow cytometry (1) 1
graft analysis (1) 1
graft characteristics (1) 1
graft composition (1) 1
graft content (1) 1
graft survival - drug effects (1) 1
graft survival - immunology (1) 1
grafting (1) 1
grafts (1) 1
granulocyte colony-stimulating factor - pharmacology (1) 1
granulocyte colony-stimulating factor - therapeutic use (1) 1
hematological recovery (1) 1
hematopoiesis (1) 1
hematopoietic stem cell mobilization (1) 1
hematopoietic stem cell transplantation (1) 1
hematopoietic stem cell transplantation - adverse effects (1) 1
hematopoietic stem cells - cytology (1) 1
heterocyclic compounds - adverse effects (1) 1
heterocyclic compounds - pharmacology (1) 1
high-dose therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia & Lymphoma, ISSN 1042-8194, 07/2019, Volume 60, Issue 9, pp. 2115 - 2121
Lymphomas constitute the second most common indication for autologous hematopoietic cell transplantation (AHCT). Graft infusion is followed by a rapid... 
immune recovery | Lymphoma | autologous hematopoietic cell transplantation | outcome | MULTIPLE-MYELOMA | NATURAL-KILLER-CELLS | AUTO-SCT | PROGRESSION-FREE SURVIVAL | AUTOGRAFT LYMPHOCYTE | ONCOLOGY | HIGH-DOSE THERAPY | COUNT RECOVERY | PLERIXAFOR INJECTION | NON-HODGKIN-LYMPHOMA | HEMATOLOGY | PREDICTS SUPERIOR SURVIVAL
Journal Article
Journal Article
Journal Article
Journal Article
Leukemia & lymphoma, 03/2019, p. 1
Lymphomas constitute the second most common indication for autologous hematopoietic cell transplantation (AHCT). Graft infusion is followed by a rapid... 
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 08/2016, Volume 9, Issue 8, pp. 723 - 732
Introduction: A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for... 
graft content | stem cell mobilization | costs | poor mobilization | myeloma | Plerixafor | lymphoma | outcome | PROGENITOR CELLS | COLONY-STIMULATING FACTOR | GRAFT CHARACTERISTICS | PHASE-II | PLUS G-CSF | CD34(+) CELLS | RAPID MOBILIZATION | PREVIOUSLY FAILING MOBILIZATION | HEMATOLOGY | PREEMPTIVE USE
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3199 - 3199
Abstract Introduction Early immune recovery after autologous transplantation has in various studies been reported to be of clinical significance in non-Hodgkin... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1193 - 1193
Abstract Introduction: Plerixafor, a reversible CXCR4 antagonist, may be used to enhance mobilization of CD34+ cells after G-CSF or chemotherapy plus G-CSF.... 
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.